MY ACCOUNT | NEWSLETTER |

AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share

Industry development with potential relevance for veterinary professionals, companion animal care, and animal health stakeholders.


Rising veterinary costs and growing owner expectations are reshaping the economics of companion animal care.

According to the announcement, AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share. The development is relevant because it reflects how animal health companies, service providers, and technology platforms are responding to changing expectations in veterinary care.

What Was Announced

Stonegate Capital Partners issued this update in a research note entitled “Stonegate Capital Partners Updates Coverage on AB Science S.A. (ENXTPA: AB) 1Q26”, published on 26 May 2026. In this update, Stonegate maintained its coverage of the stock, supported by a discounted cash flow model returning a valuation range of €3.20 to €5.77 per share, with a mid-point of €4.25 per share.

Why This Matters for Veterinary Professionals

For veterinary teams, broader insurance adoption can influence treatment acceptance, client communication, and access to advanced diagnostics or specialty care.

Financial limitations remain one of the most common barriers to advanced veterinary care. Greater insurance penetration may help some pet owners pursue diagnostics, surgery, chronic disease treatment, and preventive care with less immediate pressure from out-of-pocket costs.

Industry Perspective

The expansion of pet insurance reflects a wider shift in which financial tools are becoming part of the veterinary care conversation.

While individual announcements should be interpreted in the context of their source, they can help veterinary professionals monitor where investment, innovation, and market attention are moving across the animal health sector.

Original announcement: In this targeted patient population, AB Science — https://www.globenewswire.com/news-release/2026/06/02/3305477/0/en/ab-science-stonegate-capital-partners-updates-its-coverage-of-ab-science-s-stock-with-a-target-price-of-eur-4-25-per-share.html

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

EXPRESS: Serum vitamin D metabolites do not differ between cats with chronic kidney disease and healthy cats.

Like0
Dislike0

Assessment of Pancreatic Lipase Activity Using a Quantitative and a Qualitative Assay in Dogs with Chronic Kidney Disease.

Like0
Dislike0

Effects of oregano extracts, alone or in combination with other biomolecules, on growth performances and parasitological parameters of broiler chickens challenged with Eimeria spp.: a meta-analysis.

Like0
Dislike0

New study sets out to elevate asymptomatic COVID-19 surveillance practices

Like0
Dislike0

Dogs And Humans Are More Alike Than We Thought, Texas A&M Study Finds

Like0
Dislike1

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top